Personalized medicine is attracting attention as medical care that delivers highly effective treatments and prevention with fewer side effects based on each patient's constitution and pathological condition. Traditionally, companion diagnostics have been used to test for specific genetic mutations before treatment and select suitable therapeutic drugs. In recent years, the use of gene panel testing capable of comprehensive genetic analysis using next generation sequencing (NGS), as well as liquid biopsy that obtains genetic information from bodily fluids such as blood and urine, has progressed, advancing more comprehensive and minimally invasive personalized medicine.

At the 10 major companies, joint development of CDx with external companies, expansion into the minimal residual disease (MRD) and early detection markets, and use of data and AI technologies are important points. Through collaboration with pharmaceutical companies, advances in MRD testing technology, and the use of AI technologies and real world data (RWD), the implementation of personalized medicine is expanding, testing areas are broadening, and a structural transition to a business that provides integrated data and analysis is underway.

This survey focuses on gene panel testing and liquid biopsy, analyzes product development, research and development, partnership status, and future development and strategies at major companies, and aims to understand current business trends and clarify the future market environment and direction.

Survey Overview

Survey Purpose

Personalized medicine is attracting attention as medical care that delivers highly effective treatments and prevention with fewer side effects based on each patient's constitution and pathological condition. Traditionally, companion diagnostics have been used to test for specific genetic mutations before treatment and select suitable therapeutic drugs. In recent years, the use of gene panel testing capable of comprehensive genetic analysis using next generation sequencing (NGS), as well as liquid biopsy that obtains genetic information from bodily fluids such as blood and urine, has progressed, advancing more comprehensive and minimally invasive personalized medicine.

Among the recent trends related to gene panel testing and liquid biopsy in personalized medicine at the 10 major companies surveyed, joint development of CDx with external companies, expansion into the minimal residual disease (MRD) and early detection markets, and use of data and AI technologies are important points.

In joint development of CDx with external companies, companies aim to expand the implementation of personalized medicine through collaborations with pharmaceutical companies to expand indications, advanced NGS platforms, and expanded biomarkers. For example, Illumina is advancing the development of companion diagnostics based on the comprehensive genomic profiling test TruSight Oncology Comprehensive in collaboration with multiple global pharmaceutical companies.

In expansion into the minimal residual disease (MRD) and early detection markets, advances in MRD testing technology are expanding testing beyond conventional treatment selection support to treatment management, recurrence prediction, and early intervention. For example, Guardant Health's Guardant Reveal primarily detects postoperative MRD, but functional expansion is advancing its use to predict treatment response in various therapies including immunotherapy and chemotherapy.

In the use of data and AI technologies, each company is promoting the acquisition of AI technologies through M&A and partnerships, use of real world data (RWD), and the development of data infrastructure based on AI. As a result, a structural transition is underway from the conventional testing service business to a business that provides integrated data and analysis supporting drug discovery, development, and treatment.

This report focuses on gene panel testing and liquid biopsy and aims to understand current business trends and clarify the future market environment and direction by analyzing product development, research and development, partnership status, and future development and strategies at major companies.

Survey Period

January 2026 to February 2026

Document Format

A4 size, 172 pages

Publication Date

March 2, 2026

Survey Items (General Overview)

• 1. Survey Overview
• 2. Regulatory Framework for Personalized Medicine
  • 2-1. Regulatory Framework in Japan
  • 2-2. Regulatory Framework in the United States
  • 2-3. Regulatory Framework in Europe
• 3. Personalized Medicine Business Areas of Major Companies
• 4. Initiatives of Major Companies
  • 4-1. Product Development (IVD/CDx)
  • 4-2. Product Development (LDT, RUO)
  • 4-3. Technology and Research and Development Trends
  • 4-4. Partnership and M&A Status
• 5. Future Development and Strategies

Individual Company Section

• Sysmex (Sysmex)
• Tempus AI
• Roche
• Guardant Health
• Illumina
• Caris Life Sciences
• Thermo Fisher Scientific
• NeoGenomics Laboratories
• QIAGEN
• Natera

Survey Items (Individual Company Section)

• 1. Company Overview
• 2. Personalized Medicine Initiatives
  • 2-1. Product Development
  • 2-2. Technology and Research and Development
  • 2-3. Partnerships
• 3. Future Development and Strategies